Related Experiment Video
Updated: Dec 12, 2025
10:35
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
18.7K
Systemic therapy for non-serous ovarian carcinoma
Yanin Chávarri-Guerra1, Eduardo González-Ochoa2, Héctor De-la-Mora-Molina2
1Department of Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico. yaninchg@gmail.com.
Chinese Clinical Oncology
|August 14, 2020
Summary
Ovarian cancer encompasses various subtypes beyond high-grade serous types. This review details the unique characteristics and tailored systemic therapies for non-serous epithelial and non-epithelial ovarian cancers.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Translational Cancer Research
Background:
- Ovarian cancer is a leading cause of cancer death in women globally.
- High-grade serous epithelial ovarian cancer (EOC) is most common, but non-serous EOC and non-epithelial ovarian tumors represent significant, distinct entities.
- These diverse ovarian malignancies exhibit unique epidemiological, biological, and clinical characteristics necessitating tailored treatment approaches.
Purpose of the Study:
- To review the specific epidemiological and biological characteristics of non-serous epithelial ovarian cancer and non-epithelial ovarian tumors.
- To emphasize the distinct systemic therapy strategies required for each ovarian cancer subtype.
- To highlight the evolving landscape of ovarian cancer treatment beyond standard chemotherapy.
Main Methods:
- Literature review focusing on the classification, characteristics, and treatment of ovarian cancer subtypes.
- Analysis of current systemic treatment modalities for epithelial and non-epithelial ovarian cancers.
- Emphasis on histological subtype, molecular alterations, and patient characteristics influencing therapeutic decisions.
Main Results:
- Non-serous EOC includes endometroid, mucinous, clear cell carcinoma (CCC), and carcinosarcoma, each with unique features.
- Non-epithelial ovarian tumors (germ cell, sex-cord stromal) comprise about 10% of cases and respond well to specific chemotherapy regimens.
- Standard treatment for most EOC involves surgery followed by platinum-based chemotherapy (e.g., paclitaxel plus carboplatin), with emerging targeted therapies available.
Conclusions:
- Accurate histological subtyping is crucial for selecting optimal systemic therapy in ovarian cancer.
- Non-serous EOC and non-epithelial ovarian tumors require distinct treatment strategies compared to high-grade serous EOC.
- The field of ovarian cancer treatment is rapidly advancing with novel targeted and immune-based therapies offering new hope.
Keywords:
Carcinomaadenocarcinomacarcinosarcomaclear cellgerm cell and embryonalneoplasmsovarian epithelialovarian neoplasmssex cord-gonadal stromal tumorsMore Related Videos
Related Concept Videos
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:27Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K